LDLR and metabolic syndrome: Similarly, a study performed in a variant of the LDLr knockout mouse, that exhibits characteristics of the metabolic syndrome, showed that four weeks of treatment with carbenoxolone, a pan-11βHSD inhibitor, decreased aortic root plaque size by ∼30% vs. vehicle control [18].